Compounded GLP-1

A compounded GLP-1 is a version of semaglutide or tirzepatide mixed by a pharmacy rather than manufactured and approved as a finished product. The FDA is unambiguous about what that means: compounded drugs are not FDA-approved, and the agency does not verify their safety, effectiveness or quality before they are marketed. That is the single most important sentence in this entry.

Compounding exists for real reasons — a patient who cannot tolerate a dye in the approved product, someone who needs a different form, or a drug on FDA’s shortage list, which federal law permits compounders to copy under specified conditions. The mass-market GLP-1 compounding of recent years grew out of that shortage provision, and it has been narrowing as supply recovered.

The FDA has published specific concerns for this category. Compounded GLP-1s are often dispensed in multi-dose vials, and the agency recommends discarding a vial within 28 days of first use even if medication remains, and never reusing a needle or syringe. It has also received complaints of products arriving warm or with inadequate ice packs, and advises against using any injectable GLP-1 that arrives warm. Separately, retatrutide and cagrilintide cannot lawfully be used in compounding at all, and FDA has warned telehealth companies marketing them.

The confusion worth dispelling is the claim that a compounded drug is “the same as” the brand. FDA lists that exact claim as a telehealth red flag, along with prices that seem too good to be true and any service that dispenses without a prescription from a licensed clinician. Compounded is not generic either — a generic is approved and shown therapeutically equivalent; a compounded drug is neither.

Ask who actually compounds your medication, whether that pharmacy is a 503A pharmacy or a 503B outsourcing facility, and how it is shipped. Our pharmacy legitimacy lookup and compounded-versus-branded decision guide help you check.